Mycophenolate Add-on Therapy Is Effective in Severe IgA Nephropathy
BACKGROUND: IgA Nephropathy (IgAN) is the most common primary glomerulonephritis. There is limited evidence on the use of mycophenolate mofetil (MMF) in IgAN in non-Asian populations. This study evaluates the efficacy of MMF in IgAN. METHODS: Retrospective cohort study of patients with biopsy-confirmed IgAN between 2013 and 2024, with at least 6 months of follow-up. Patients were classified into three groups based on the treatment received in the first 6 months after diagnosis: (1) Supportive care, (2) Corticosteroids, (3) MMF add-on. Data were collected at baseline, 3, 6, 12, and 24 months. Changes in estimated glomerular filtration rate (eGFR), urinary protein-to-creatinine ratio (UPCR) and hematuria were assessed. The composite outcome included eGFR <15 mL/min/1.73 m2, kidney replacement therapy, the need for additional immunosuppressive therapy, kidney transplantation, or death assessed over a median follow-up of 43 months. Outcomes evaluated included eGFR below 15 ml/min/1.73m2, initiation of dialysis, transplantation, another immunosuppressant or death. RESULTS: Sixty-four patients were included: 19 MMF add-on, 14 Corticosteroids, and 31 Supportive care. Patients in the MMF add-on and corticosteroid groups had a more severe clinical profile compared to the Supportive care group. At 24 months, the MMF add-on and corticosteroids group showed a greater UPCR reduction compared to the Supportive care group (reduction of 57% p = 0.02 for both groups). In the MMF add-on group, hematuria reduction was significantly greater and renal function improved from the third month. CONCLUSIONS: Patients treated with MMF had similar outcomes to the supportive care group, despite having significantly more severe disease at baseline. These results suggest that MMF add-on could be a potential treatment for non-Asian patients with severe IgAN.
Authors
- Sheila Bermejo (ORCID: https://orcid.org/0000-0002-3611-4830)
- Laia Sans (ORCID: https://orcid.org/0000-0002-3628-9489)
- Ehimy Marcela Suárez Barajas (ORCID: https://orcid.org/0009-0006-7101-2895)
- Oriol Bestard (ORCID: https://orcid.org/0000-0001-9468-7920)
- Juan Carlos León Román
- Natalia Ramos-Terrades (ORCID: https://orcid.org/0000-0001-9832-326X)
- María José Soler (ORCID: https://orcid.org/0000-0003-3621-0766)
- Federico Yandián (ORCID: https://orcid.org/0000-0001-8374-9508)
- Alejandra Gabaldón (ORCID: https://orcid.org/0000-0002-0149-6955)
- Sara Núñez-Delgado (ORCID: https://orcid.org/0000-0002-3481-2520)
- Marina López-Martínez (ORCID: https://orcid.org/0000-0003-4284-831X)
- Efrain Tatis (ORCID: https://orcid.org/0009-0003-5474-0135)
- Tiffany Alvarez (ORCID: https://orcid.org/0009-0004-0365-5683)
- Irene Agraz
Institutions
- Hebron University (PS)
- Vall d'Hebron Institut de Recerca (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Sistema Nacional de Salud (ES)
Publication Details
- Journal
- Kidney360
- Published
- 2026-11-18
- DOI
- https://doi.org/10.34067/kid.0000001443
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00